Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: ETHOS study

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Alavi, Maryam ^a   Grebely, Jason ^a   Micallef, Michelle ^a   Dunlop, Adrian J ^b,c   Balcomb, Annie C ^d   Day, Carolyn A ^e,f   Treloar, Carla ^g   Bath, Nicky ^h   Haber, Paul S ^e,f   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Drug and Alcohol Service   (United Kingdom)

^d Clinic 96   (United States)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h NSW Users   (Australia)

Author keywords

Drug users; HCV; Integrated care; Opioid substitution; PWID

Indexed keywords

BENZODIAZEPINE; DIAMORPHINE; METHADONE; METHAMPHETAMINE; MORPHINE; OPIATE; PSEUDOCOCAINE;

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE ORGANIZATION; HEALTH CENTER; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIAL SUPPORT;

DRUG USERS; HCV; INTEGRATED CARE; OPIOID SUBSTITUTION; PWID;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84881012747     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit305     Document Type: Article

References (29)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-9.
3. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56: 806-16.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
6. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. New Engl J Med 2011; 364: 2199-207.
7. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
8. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who use drugs: one size does not fit all. Clin Infect Dis 2013; 57(Suppl 2):S56-61.
9. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4:20.
10. Martinez A, Dimova R, Marks K, et al. Integrated internist-addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19: 47-54.
11. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El- Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106: 483-91.
12. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18:e104-16.
13. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev 2012; 31: 918-24.
14. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-9.
15. Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Australia 2010; 192: 496-500.
16. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Australia 2011; 194: 398-402.
17. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
18. Henry JD, Crawford Jr. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Brit J Clin Psychol 2005; 44(Pt 2): 227-39.
19. Lawrinson P, Copeland J, Indig D. Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: the brief treatment outcome measure (BTOM). Drug Alcohol Depend 2005; 80: 125-33.
20. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158:1789.
21. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
22. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19: 357-65.
23. Iversen J, Grebely J, Topp L, et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011 [published online ahead of print 1 July 2013]. J Viral Hepat 2013; doi:10.1111/jvh.12129.
24. Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2: 116-24.
25. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88: 49-53.
26. Paquette D, McEwan M, Bryant J. Risk practices among aboriginal people who inject drugs in New South Wales, Australia. AIDS Behav 2012: 1-7.
27. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012; 125: 8-18.
28. Degenhardt L, Mathers B, Guarinieri M, et al. Meth/amphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy 2010; 21: 347-58.
29. Degenhardt L, Mathers B, Guarinieri M, et al. The global epidemiology of methamphetamine injection: a review of the evidence on use and associations with HIV and other harm. Sydney, Australia: National Drug and Alcohol Research Centre, University of New SouthWales, 2007.